Page 132 - Haematologica-5

864
P. Schommers et al.
the German AIDS-related lymphoma
cohort study. Aids. 2013;27(5):842-845.
17. Schommers P, Hentrich M, Hoffmann C, et al. Survival of AIDS-related diffuse large B- cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol.
2015;168(6):806-810.
18. Barta SK, Xue X, Wang D, et al. A new
prognostic score for AIDS-related lym- phomas in the rituximab-era. Haematologica. 2014;99(11):1731-1737.
19. Hentrich M, Hoffmann C, Mosthaf F, et al. Therapy of HIV-associated lymphoma-rec- ommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV- Infected Patients (DAGNA), in cooperation with the German AIDS Society (DAIG). Ann Hematol. 2014;93(6):913-921.
20. Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14)
with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250-1259.
Ann Hematol. 2010;89(9):897-904.
24. Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong pre- dictor of AIDS-related lymphoma. J Infect
Dis. 2009;200(1):79-87.
25. Younes A, Hilden P, Coiffier B, et al.
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436-
21. Barta SK, Xue X, Wang D, et al. Treatment
factors affecting outcomes in HIV-associat-
ed non-Hodgkin lymphomas: a pooled
analysis of 1546 patients. Blood. 2013; 122(19):3251-3262. 1447
22. Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008; 87(4):277-283.
23. Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K. Importance of main- taining the relative dose intensity of CHOP- like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
26. Mhlanga JC, Durand D, Tsai HL, et al. Differentiation of HIV-associated lym- phoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):596-604.
27. Sathekge M. Differentiation of HIV-associ- ated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):593-595.
haematologica | 2018; 103(5)